Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ASMB

Assembly Biosciences Inc

Feb 12 • 04:00PM ET

26.09

-1.27 -4.64 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD ABUS IONS ENTA MDGL NBIX VKTX ADAP OMER LXRX

| Held by: VTI VXF IWC BBC AVSC

Index	-	P/E	-	EPS (ttm)	-4.80	Insider Own	36.93%	Shs Outstand	15.82M	Perf Week	2.76%
Market Cap	412.67M	Forward P/E	-	EPS next Y	-4.04	Insider Trans	0.00%	Shs Float	9.98M	Perf Month	-17.44%
Enterprise Value	182.86M	PEG	-	EPS next Q	-0.86	Inst Own	50.83%	Short Float	15.41%	Perf Quarter	-21.25%
Income	-38.55M	P/S	11.10	EPS this Y	43.95%	Inst Trans	28.50%	Short Ratio	12.18	Perf Half Y	5.41%
Sales	37.19M	P/B	2.26	EPS next Y	-7.66%	ROA	-22.66%	Short Interest	1.54M	Perf YTD	-23.29%
Book/sh	11.55	P/C	1.77	EPS next 5Y	-	ROE	-36.94%	52W High	39.71 -34.29%	Perf Year	107.56%
Cash/sh	14.70	P/FCF	-	EPS past 3/5Y	42.93% 31.58%	ROIC	-20.85%	52W Low	7.75 236.65%	Perf 3Y	44.94%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	65.83% 12.31%	Gross Margin	99.65%	Volatility	5.57% 6.50%	Perf 5Y	-65.43%
Dividend TTM	-	EV/Sales	4.92	EPS Y/Y TTM	32.79%	Oper. Margin	-116.83%	ATR (14)	1.81	Perf 10Y	-59.96%
Dividend Ex-Date	-	Quick Ratio	4.44	Sales Y/Y TTM	31.30%	Profit Margin	-103.65%	RSI (14)	40.58	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.44	EPS Q/Q	52.10%	SMA20	-3.71%	Beta	1.14	Target Price	47.75
Payout	-	Debt/Eq	0.02	Sales Q/Q	57.62%	SMA50	-15.85%	Rel Volume	0.80	Prev Close	27.36
Employees	73	LT Debt/Eq	0.01	Earnings	Nov 10 AMC	SMA200	5.87%	Avg Volume	126.30K	Price	26.09
IPO	Dec 17, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.33% 44.64%	Trades		Volume	101,613	Change	-4.64%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-25	Initiated	Citizens JMP	Mkt Outperform	$38
Aug-18-25	Resumed	H.C. Wainwright	Buy	$50
Mar-25-25	Initiated	Guggenheim	Buy	$31
Sep-20-24	Upgrade	Jefferies	Hold → Buy	$2 → $35
Sep-13-21	Initiated	H.C. Wainwright	Neutral	$3.50
Sep-02-21	Downgrade	William Blair	Outperform → Mkt Perform
Mar-23-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-06-20	Downgrade	Jefferies	Buy → Hold	$30 → $10
Oct-19-20	Initiated	Truist	Buy	$55
Oct-16-19	Initiated	Mizuho	Buy	$20
Nov-19-18	Initiated	Leerink Partners	Outperform	$45
Oct-08-18	Upgrade	B. Riley FBR	Neutral → Buy	$42
Aug-08-18	Initiated	Robert W. Baird	Outperform	$74
Apr-13-18	Downgrade	Chardan Capital Markets	Buy → Neutral	$35 → $50
Jan-05-18	Initiated	B. Riley FBR, Inc.	Neutral	$35
Nov-08-17	Initiated	Jefferies	Buy	$50
May-30-17	Initiated	Chardan Capital Markets	Buy	$35

Show Previous Ratings

Dec-23-25 10:45AM	GILD Exercises Option to License Assembly Bio's Herpes Programs (Zacks) -9.54%
Dec-22-25 08:00AM	Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes (Business Wire)
Dec-08-25 04:05PM	Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes (GlobeNewswire)
Nov-10-25 04:18PM	Assembly Biosciences: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates (GlobeNewswire)
08:00AM	Loading…
Nov-07-25 08:00AM	Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting (GlobeNewswire)
Nov-04-25 05:20PM	Supernus Pharmaceuticals (SUPN) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Oct-29-25 11:57AM	H.C. Wainwright Reaffirms Buy Rating on Assembly Biosciences, Inc. (ASMB) Amid Promising Trial Data (Insider Monkey)
Oct-14-25 07:00AM	Assembly Biosciences Announces Upcoming Investor Conference Participation (GlobeNewswire)
Oct-10-25 08:00AM	Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe (GlobeNewswire)
Sep-25-25 09:40AM	Amazon upgraded, Adobe downgraded: Wall Streets top analyst calls (TipRanks)
Sep-24-25 09:36AM	Amazon upgraded, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Sep-22-25 10:32AM	Assembly Biosciences (ASMB) Surges 9.8%: Is This an Indication of Further Gains? (Zacks)
Aug-11-25 07:26AM	Assembly Bios herpes drug shows 94% drop in viral shedding (Clinical Trials Arena)
Aug-08-25 08:05AM	Assembly Biosciences Announces Pricing of $175 Million in Equity Financings (GlobeNewswire) +12.96%
08:00AM	Loading…
08:00AM	Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes (GlobeNewswire)
Aug-06-25 05:20PM	Assembly Biosciences: Q2 Earnings Snapshot (Associated Press Finance) +9.21%
04:05PM	Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates (GlobeNewswire)
04:05PM	Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus (GlobeNewswire)
Jul-26-25 03:00AM	Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop (GlobeNewswire)
Jul-24-25 11:48PM	Assembly Bio's (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial (Insider Monkey)
Jul-02-25 10:09PM	Assembly Biosciences, Inc. (ASMB) Announces Key Leadership and Plan Changes (Insider Monkey)
Jul-01-25 10:50AM	First subject dosed in Assembly Biosciences study for genital herpes (Clinical Trials Arena)
Jun-30-25 08:00AM	Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179 (GlobeNewswire)
Jun-25-25 08:00AM	Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B (GlobeNewswire)
May-27-25 04:05PM	Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference (GlobeNewswire)
May-08-25 05:40PM	Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.04%
04:36PM	Assembly Biosciences: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates (GlobeNewswire)
May-07-25 05:35PM	Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates (Zacks)
08:00AM	Loading…
08:00AM	New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025 (GlobeNewswire)
May-05-25 09:47AM	Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-29-25 05:35PM	BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.38%
Apr-09-25 02:00AM	Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress (GlobeNewswire)
Apr-08-25 09:35AM	Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround (Zacks)
Mar-26-25 12:00PM	Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) -5.34%
Mar-20-25 04:53PM	Assembly Biosciences files for $250 mixed securities shelf (SeekingAlpha)
04:05PM	Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights (GlobeNewswire)
Mar-04-25 08:34PM	Is Assembly Biosciences, Inc. (ASMB) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
Feb-26-25 08:00AM	Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus (GlobeNewswire) +7.86%
Feb-20-25 08:00AM	Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes (GlobeNewswire)
Dec-29-24 03:00AM	Gilead Buys $20.1 Million of Assembly Biosciences Stock (Barrons.com)
Dec-26-24 08:00AM	Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B (GlobeNewswire)
Dec-19-24 08:00AM	Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs (GlobeNewswire) +17.02%
Nov-07-24 06:19PM	Assembly Biosciences: Q3 Earnings Snapshot (Associated Press Finance) +5.11%
04:05PM	Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates (GlobeNewswire)
Sep-23-24 01:39PM	Assembly Biosciences' Investigational Herpes Treatment Shows Safety In Healthy Participants (UPDATED) (Benzinga) -16.31%
08:00AM	Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 (GlobeNewswire)
Sep-16-24 09:40AM	Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-08-24 05:22PM	Assembly Biosciences: Q2 Earnings Snapshot (Associated Press Finance) +6.02%
04:05PM	Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates (GlobeNewswire)
Jul-15-24 08:00AM	Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop (GlobeNewswire)
Jun-18-24 08:00AM	Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection (GlobeNewswire)
Jun-17-24 08:00AM	Assembly Biosciences Announces $12.6 Million in Equity Financings (GlobeNewswire)
Jun-10-24 08:00AM	Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366 (GlobeNewswire) +6.51%
Jun-05-24 08:00AM	Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress 2024 (GlobeNewswire)
May-22-24 08:00AM	Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress 2024 (GlobeNewswire)
May-13-24 08:53AM	ASMB Stock Earnings: Assembly Biosciences Beats EPS for Q1 2024 (InvestorPlace)
May-09-24 05:04AM	Assembly Biosciences: Q1 Earnings Snapshot (Associated Press Finance)
May-08-24 04:05PM	Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Mar-28-24 10:53PM	ASMB Stock Earnings: Assembly Biosciences Beats EPS for Q4 2023 (InvestorPlace)
04:05PM	Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights (GlobeNewswire)
Mar-25-24 12:52PM	ASMB Stock Earnings: Assembly Biosciences Misses EPS for Q2 2023 (InvestorPlace)
Feb-08-24 08:00AM	Assembly Biosciences Announces Effective Date of Reverse Stock Split (GlobeNewswire)
Jan-04-24 08:00AM	Assembly Biosciences Provides Anticipated Development Milestones for 2024 (GlobeNewswire)
Nov-10-23 04:05PM	Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.11%
08:00AM	Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting (GlobeNewswire)
Nov-08-23 05:08PM	Assembly Biosciences: Q3 Earnings Snapshot (Associated Press Finance) -12.48%
04:05PM	Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates (GlobeNewswire)
08:00AM	Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer (GlobeNewswire)
Oct-17-23 10:59AM	Why Is Assembly Biosciences (ASMB) Stock Up 92% Today? (InvestorPlace) +72.18%
07:00AM	Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases (Business Wire)
Oct-11-23 08:00AM	Assembly Biosciences to Present New Data at AASLD The Liver Meeting (GlobeNewswire)
Oct-02-23 08:00AM	Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor (GlobeNewswire)
Sep-19-23 04:05PM	Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting (GlobeNewswire) -5.72%
Aug-09-23 06:11PM	Assembly Biosciences: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates (GlobeNewswire)
Jul-17-23 08:00AM	Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop (GlobeNewswire)
Jun-21-23 08:00AM	Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASLs International Liver Congress 2023 (GlobeNewswire)
Jun-07-23 08:00AM	Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress 2023 (GlobeNewswire)
May-23-23 04:05PM	Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-04-23 06:28PM	Assembly Biosciences: Q1 Earnings Snapshot (AP Finance)
04:05PM	Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Apr-18-23 08:00AM	Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update (GlobeNewswire)
Mar-30-23 10:04AM	Companies Like Assembly Biosciences (NASDAQ:ASMB) Could Be Quite Risky (Simply Wall St.) -10.11%
Mar-22-23 04:05PM	Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights (GlobeNewswire) -8.55%
Feb-15-23 08:00AM	Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes (GlobeNewswire)
Dec-19-22 03:19PM	Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs (Benzinga) +14.53%
08:00AM	Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334 (GlobeNewswire)
Nov-14-22 08:00AM	Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334 (GlobeNewswire) +8.21%
Nov-09-22 09:35AM	After Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB) (Zacks)
Nov-08-22 04:05PM	Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation (GlobeNewswire) -7.43%
Nov-04-22 08:00AM	Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV (GlobeNewswire) -5.00%
Oct-24-22 08:00AM	Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting® (GlobeNewswire)
Oct-21-22 09:36AM	Can Assembly Biosciences (NASDAQ:ASMB) Afford To Invest In Growth? (Simply Wall St.)
Oct-05-22 04:05PM	Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor (GlobeNewswire)
Aug-24-22 08:00AM	Assembly Biosciences to Host Webcast on August 31, 2022, Introducing Two New Research Programs Targeting Recurrent HSV-2 Infection and Transplant-Associated Herpesvirus Diseases (GlobeNewswire)
Aug-09-22 04:05PM	Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights (GlobeNewswire)
Aug-04-22 12:00PM	Assembly Biosciences (ASMB) Upgraded to Strong Buy: Here's Why (Zacks)
10:00AM	Best Momentum Stocks to Buy for August 4th (Zacks)

Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. Its lead programs, ABI-5366 and ABI-1179, long-acting helicase-primase inhibitors, are in clinical development for recurrent genital herpes. The company is partnered with Gilead Sciences to advance current and future antiviral programs across herpesviruses, HBV, and HDV. Assembly Biosciences was founded in 2005 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McHutchison John G	Director	Mar 31 '25	Sale	9.85	757	7,455	18,347	Apr 15 05:30 PM
Bjorkquist Jeanette M	Principal Accounting Officer	Mar 31 '25	Sale	9.85	180	1,773	4,617	Apr 01 04:05 PM
Okazaki Jason A	CEO and President	Mar 31 '25	Sale	9.85	355	3,496	14,757	Apr 01 04:05 PM
White Nicole S	Chief Manufacturing Officer	Mar 31 '25	Sale	9.85	197	1,940	11,674	Apr 01 04:05 PM

Open in Screener

RCUS

Arcus Biosciences Inc

Feb 12 • 04:00PM ET

19.96

-1.40 -6.55 %

Healthcare • Biotechnology • USA • NYSE

RCUS Arcus Biosciences Inc daily Stock Chart

Peers: BMY MRK PFE JNJ GILD ABBV NVS LLY REGN VRTX

| Held by: IJR VTI IWM XBI VXF VB SPSM VBK IBB IWO

Index	RUT	P/E	-	EPS (ttm)	-3.43	Insider Own	34.38%	Shs Outstand	107.10M	Perf Week	-0.35%
Market Cap	2.47B	Forward P/E	-	EPS next Y	-3.97	Insider Trans	-1.24%	Shs Float	81.19M	Perf Month	-12.23%
Enterprise Value	1.75B	PEG	-	EPS next Q	-1.11	Inst Own	56.00%	Short Float	10.10%	Perf Quarter	-1.63%
Income	-341.00M	P/S	10.29	EPS this Y	-14.22%	Inst Trans	1.78%	Short Ratio	5.04	Perf Half Y	98.41%
Sales	240.00M	P/B	4.90	EPS next Y	-10.64%	ROA	-30.64%	Short Interest	8.20M	Perf YTD	-16.24%
Book/sh	4.07	P/C	2.97	EPS next 5Y	-1.58%	ROE	-68.13%	52W High	26.40 -24.39%	Perf Year	66.33%
Cash/sh	6.72	P/FCF	-	EPS past 3/5Y	- -10.20%	ROIC	-63.86%	52W Low	6.50 207.08%	Perf 3Y	-0.84%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-12.33% 76.65%	Gross Margin	95.83%	Volatility	5.53% 5.94%	Perf 5Y	-44.56%
Dividend TTM	-	EV/Sales	7.29	EPS Y/Y TTM	-8.79%	Oper. Margin	-156.25%	ATR (14)	1.24	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.65	Sales Y/Y TTM	-8.75%	Profit Margin	-142.08%	RSI (14)	40.98	Recom	1.55
Dividend Gr. 3/5Y	- -	Current Ratio	3.65	EPS Q/Q	-25.93%	SMA20	-7.72%	Beta	0.85	Target Price	32.30
Payout	-	Debt/Eq	0.25	Sales Q/Q	-45.83%	SMA50	-11.77%	Rel Volume	1.15	Prev Close	21.36
Employees	627	LT Debt/Eq	0.22	Earnings	Feb 25 AMC	SMA200	33.67%	Avg Volume	1.63M	Price	19.96
IPO	Mar 15, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.05% 23.81%	Trades		Volume	1,864,375	Change	-6.55%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-12-26	Downgrade	Wells Fargo	Overweight → Equal Weight	$23
Jan-13-26	Upgrade	Goldman	Neutral → Buy	$28
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$20
Feb-26-25	Upgrade	H.C. Wainwright	Neutral → Buy	$18 → $24
Oct-21-24	Initiated	H.C. Wainwright	Neutral	$20
Oct-08-24	Initiated	Wells Fargo	Overweight	$29
Nov-18-22	Initiated	BofA Securities	Neutral	$33
Oct-11-22	Initiated	Morgan Stanley	Overweight	$40
Oct-15-21	Resumed	BTIG Research	Buy	$57
Nov-24-20	Initiated	Berenberg	Buy	$50
Nov-23-20	Initiated	Evercore ISI	Outperform
Apr-03-20	Initiated	Cantor Fitzgerald	Overweight	$21
Mar-04-20	Initiated	Barclays	Overweight	$24
Nov-12-19	Initiated	SunTrust	Buy	$20
Sep-27-19	Initiated	Mizuho	Buy	$22
May-24-19	Resumed	Citigroup	Buy	$25
Oct-09-18	Initiated	Wedbush	Outperform	$22
Apr-09-18	Initiated	Leerink Partners	Outperform	$21
Apr-09-18	Initiated	Goldman	Neutral	$18
Apr-09-18	Initiated	Citigroup	Buy	$18

Show Previous Ratings

Feb-11-26 04:05PM	Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates (Business Wire) -6.55%
10:15AM	GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales (Zacks)
Feb-05-26 07:58AM	Rapid Innovation is Reshaping Oncology: Stocks in Focus (Zacks)
Feb-04-26 09:55AM	Wall Street Analysts See a 57.56% Upside in Arcus Biosciences (RCUS): Can the Stock Really Move This High? (Zacks)
Jan-26-26 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
04:05PM	Loading…
Jan-07-26 04:05PM	Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs (Business Wire) +6.96% -7.97%
Dec-18-25 04:05PM	Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-17-25 07:30AM	This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell? (Barchart)
Dec-15-25 09:59AM	RCUS Stock Down on Decision to Discontinue GILD Partnered Study (Zacks)
Dec-12-25 04:10PM	Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak (Investor's Business Daily) -14.36%
08:30AM	Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio (Business Wire)
06:47AM	Arcus cancels work on Gilead-partnered cancer combo after trial setback (BioPharma Dive)
Dec-09-25 06:00PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Nov-18-25 04:05PM	Arcus Biosciences to Participate in Two Upcoming Investor Conferences (Business Wire)
Oct-30-25 11:35PM	Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock (Business Wire)
04:01PM	Loading…
04:01PM	Arcus Biosciences Announces Commencement of Public Offering of Common Stock (Business Wire)
Oct-28-25 05:55PM	Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Beats Revenue Estimates (Zacks) +6.88%
04:05PM	Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update (Business Wire)
05:23AM	Arcus Biosciences (RCUS) Surges 7.5%: Is This an Indication of Further Gains? (Zacks)
Oct-26-25 06:16AM	Arcus Biosciences Inc. (RCUS) Posts Positive Results on Kidney Cancer Drug Trials (Insider Monkey)
Oct-19-25 07:00PM	Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia (Business Wire)
Oct-12-25 06:05PM	Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study (Business Wire)
Oct-09-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Oct-07-25 04:04PM	How Arcus Biosciences Aims To Take On Merck In Cancer Treatment (Investor's Business Daily) +7.27%
09:40AM	Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock? (Zacks)
Oct-06-25 08:00AM	Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event (Business Wire) +8.46%
Sep-24-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Sep-08-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) -6.15%
Sep-02-25 04:05PM	Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation (Business Wire) +7.68%
Aug-20-25 04:05PM	Arcus Biosciences to Participate in Three Upcoming Investor Conferences (Business Wire)
10:07PM	Loading…
Aug-15-25 10:07PM	Jim Cramer on Arcus Biosciences: "Let This Be Your Speculation" (Insider Monkey)
Aug-13-25 08:56PM	Lightning Round: Arcus Biosciences is speculative, it's too risky to fully bank on, says Jim Cramer (CNBC TV)
Aug-06-25 06:10PM	Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2 (Zacks)
04:05PM	Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update (Business Wire)
Aug-05-25 05:35PM	Pacira (PCRX) Tops Q2 Earnings Estimates (Zacks)
Jul-24-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Jul-10-25 08:30AM	Arcus Biosciences Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer (Business Wire)
Jul-09-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) +9.76%
Jul-01-25 02:42AM	Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment (Insider Monkey)
Jun-24-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Jun-10-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) -9.38%
Jun-01-25 10:45AM	Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response (Business Wire)
May-27-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
May-09-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) +6.28%
May-07-25 10:14AM	Q1 2025 Arcus Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
03:21AM	Arcus Biosciences Inc (RCUS) Q1 2025 Earnings Call Highlights: Strategic Focus and Financial ... (GuruFocus.com)
May-06-25 06:05PM	Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -9.17%
04:05PM	Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update (Business Wire)
May-05-25 09:56AM	Earnings To Watch: Arcus Biosciences Inc (RCUS) Reports Q1 2025 Result (GuruFocus.com)
Apr-24-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Apr-23-25 04:05PM	Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting (Business Wire)
Apr-22-25 04:05PM	Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update (Business Wire)
Apr-09-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) +12.78% -5.54%
Apr-02-25 03:48PM	Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts (Seeking Alpha)
Mar-25-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) -7.89%
Mar-14-25 11:25AM	Arcus Biosciences, Inc. (RCUS): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-03-25 02:45PM	Arcus Biosciences (RCUS): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-26-25 04:35PM	Arcus Biosciences to Participate in Two Upcoming Investor Conferences (Business Wire)
Feb-25-25 06:00PM	Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update (Business Wire)
01:38AM	Arcus Biosciences Inc (RCUS) Q4 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Feb-24-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) -8.22%
Feb-18-25 08:40AM	Arcus says new data demonstrated best-in-class potential for casdatifan (TipRanks) -16.34%
06:57AM	Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering (Business Wire)
06:52AM	Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock (Business Wire)
Feb-15-25 03:45PM	New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer (Business Wire)
Feb-11-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Feb-10-25 05:00PM	Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium (Business Wire)
Jan-24-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Jan-21-25 04:05PM	Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer (Business Wire) -5.23%
Dec-24-24 04:05PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Dec-19-24 04:05PM	Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-10-24 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Dec-03-24 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Dec-02-24 10:18AM	Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend (PR Newswire)
Nov-19-24 04:05PM	Arcus Biosciences to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-12-24 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) -5.52%
Nov-07-24 02:26AM	Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Nov-06-24 05:35PM	Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:22PM	Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update (Business Wire)
Nov-05-24 09:00AM	Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer (Business Wire)
07:48AM	What To Expect From Arcus Biosciences Inc (RCUS) Q3 2024 Earnings (GuruFocus.com)
Oct-30-24 10:01AM	Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:00AM	Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting (Business Wire)
Oct-24-24 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) -8.47%
07:30AM	First Clinical Data for Arcus Biosciences HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer (Business Wire)
Oct-22-24 04:05PM	Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update (Business Wire)
Oct-17-24 03:02PM	State Street Corp's Strategic Adjustment in Arcus Biosciences Holdings (GuruFocus.com)
Oct-09-24 06:03PM	Arcus Biosciences Inc (RCUS) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
08:00AM	Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium (Business Wire)
Oct-02-24 04:05PM	Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma (Business Wire)
Sep-24-24 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Sep-10-24 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Aug-28-24 02:33PM	Arcus Biosciences obtains loan facility with Hercules Capital worth $250m (Pharmaceutical Technology)
Aug-27-24 04:05PM	Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital (Business Wire)
Aug-26-24 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Aug-21-24 04:05PM	Arcus Biosciences to Participate in Two Upcoming Investor Conferences (Business Wire)
Aug-16-24 04:52AM	Nuntius partners with Taiho to develop mRNA cancer therapies (Pharmaceutical Technology)
Aug-08-24 06:15PM	Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +14.02%

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jaen Juan C.	President	Jan 05 '26	Sale	21.41	31,823	681,342	922,240	Jan 07 04:15 PM
Juan Jaen	Officer	Jan 05 '26	Proposed Sale	21.77	31,823	692,787		Jan 05 04:58 PM
Goeltz II Robert C.	Chief Financial Officer	Dec 31 '25	Sale	23.38	6,552	153,186	67,924	Jan 02 04:19 PM
Robert C. Goeltz II	Officer	Dec 31 '25	Proposed Sale	23.38	6,552	153,186		Dec 31 06:26 PM
Tang Carolyn C.	General Counsel	Dec 16 '25	Sale	21.88	7,658	167,590	131,544	Dec 18 05:35 PM
Tang Carolyn C.	General Counsel	Dec 17 '25	Sale	22.16	6,810	150,906	124,734	Dec 18 05:35 PM
Markus Richard	Chief Medical Officer	Dec 16 '25	Sale	21.88	5,052	110,559	70,141	Dec 18 05:35 PM
Markus Richard	Chief Medical Officer	Dec 17 '25	Sale	22.16	4,494	99,585	65,647	Dec 18 05:35 PM
Azoy Alexander	Chief Accounting Officer	Dec 18 '25	Sale	22.25	4,343	96,614	18,531	Dec 18 05:35 PM
Azoy Alexander	Chief Accounting Officer	Dec 16 '25	Sale	21.88	2,376	51,997	24,987	Dec 18 05:35 PM
Azoy Alexander	Chief Accounting Officer	Dec 17 '25	Sale	22.16	2,113	46,823	22,874	Dec 18 05:35 PM
Goeltz II Robert C.	Chief Financial Officer	Dec 16 '25	Sale	21.88	6,702	146,669	80,436	Dec 18 05:35 PM
Goeltz II Robert C.	Chief Financial Officer	Dec 17 '25	Sale	22.16	5,960	132,071	74,476	Dec 18 05:35 PM
Jarrett Jennifer	Chief Operating Officer	Dec 16 '25	Sale	21.88	11,225	245,651	203,007	Dec 18 05:35 PM
Jarrett Jennifer	Chief Operating Officer	Dec 17 '25	Sale	22.16	9,983	221,218	193,024	Dec 18 05:35 PM
Jaen Juan C.	President	Dec 16 '25	Sale	21.88	11,225	245,651	355,995	Dec 18 05:35 PM
Jaen Juan C.	President	Dec 17 '25	Sale	22.16	9,983	221,218	346,012	Dec 18 05:35 PM
ROSEN TERRY J	Chief Executive Officer	Dec 16 '25	Sale	21.88	28,947	633,485	2,220,553	Dec 18 05:35 PM
ROSEN TERRY J	Chief Executive Officer	Dec 17 '25	Sale	22.16	25,744	570,474	2,194,809	Dec 18 05:35 PM
ALEXANDER AZOY	Officer	Dec 18 '25	Proposed Sale	22.28	4,343	96,762		Dec 18 04:23 PM
Richard Markus	Officer	Dec 16 '25	Proposed Sale	21.90	10,000	219,000		Dec 15 06:23 PM
Carolyn Tang	Officer	Dec 16 '25	Proposed Sale	21.90	15,000	328,500		Dec 15 06:22 PM
Alexander Azoy	Officer	Dec 16 '25	Proposed Sale	21.90	5,000	109,500		Dec 15 06:22 PM
Robert C. Goeltz, II	Officer	Dec 16 '25	Proposed Sale	21.90	14,000	306,600		Dec 15 06:21 PM
Jennifer Jarrett	Officer	Dec 16 '25	Proposed Sale	21.90	22,000	481,800		Dec 15 06:21 PM
Juan Jaen	Officer	Dec 16 '25	Proposed Sale	21.90	22,000	481,800		Dec 15 06:20 PM
Terry Rosen, Ph.D.	Officer	Dec 16 '25	Proposed Sale	21.90	55,000	1,204,500		Dec 15 06:19 PM
Jaen Juan C.	President	Dec 04 '25	Sale	24.71	82,997	2,050,599	954,063	Dec 05 04:15 PM
Juan Jaen	Officer	Dec 04 '25	Proposed Sale	25.26	82,997	2,096,504		Dec 04 05:10 PM
Azoy Alexander	Chief Accounting Officer	Nov 26 '25	Option Exercise	13.33	1,900	25,327	29,263	Dec 01 06:09 PM
Azoy Alexander	Chief Accounting Officer	Nov 26 '25	Sale	26.00	1,900	49,400	27,363	Dec 01 06:09 PM
ALEXANDER AZOY	Officer	Nov 26 '25	Proposed Sale	24.28	1,900	46,132		Nov 26 04:20 PM
Goeltz II Robert C.	Chief Financial Officer	Nov 26 '25	Sale	25.00	5,000	125,000	87,138	Nov 26 04:07 PM
Robert C. Goeltz II	Officer	Nov 26 '25	Proposed Sale	25.00	5,000	125,000		Nov 26 03:12 PM
Jaen Juan C.	President	Nov 17 '25	Sale	20.31	44,950	913,027	1,042,110	Nov 19 04:39 PM
Jaen Juan C.	President	Nov 18 '25	Sale	19.75	5,050	99,738	1,037,060	Nov 19 04:39 PM
Juan Jaen	Officer	Nov 17 '25	Proposed Sale	19.99	50,000	999,500		Nov 17 06:27 PM
Jarrett Jennifer	Chief Operating Officer	Nov 07 '25	Option Exercise	1.23	50,291	61,737	264,523	Nov 12 04:04 PM
Jarrett Jennifer	Chief Operating Officer	Nov 07 '25	Sale	18.97	50,291	954,066	214,232	Nov 12 04:04 PM
Jaen Juan C.	President	Oct 30 '25	Sale	20.32	4,314	87,650	1,087,060	Nov 03 04:46 PM
Juan Jaen	Officer	Oct 30 '25	Proposed Sale	20.19	1,173	23,683		Oct 30 06:21 PM
Jaen Juan C.	President	Oct 29 '25	Sale	20.90	77,840	1,626,634	1,091,374	Oct 30 08:49 AM
Jaen Juan C.	President	Oct 28 '25	Sale	20.19	19,019	383,944	1,169,214	Oct 30 08:49 AM
Goeltz II Robert C.	Chief Financial Officer	Oct 28 '25	Sale	20.00	5,000	100,000	92,138	Oct 29 08:54 AM
Robert C. Goeltz II	Officer	Oct 28 '25	Proposed Sale	20.00	5,000	100,000		Oct 28 05:13 PM
Juan Jaen	Officer	Oct 28 '25	Proposed Sale	19.88	100,000	1,988,000		Oct 28 05:09 PM
Jarrett Jennifer	Chief Operating Officer	Oct 08 '25	Option Exercise	1.23	37,792	46,393	252,024	Oct 08 07:08 PM
Jarrett Jennifer	Chief Operating Officer	Oct 06 '25	Option Exercise	1.23	12,500	15,345	226,732	Oct 08 07:08 PM
Jarrett Jennifer	Chief Operating Officer	Oct 08 '25	Sale	15.05	37,792	568,611	214,232	Oct 08 07:08 PM
Jarrett Jennifer	Chief Operating Officer	Oct 06 '25	Sale	14.54	12,500	181,801	214,232	Oct 08 07:08 PM
Jennifer Jarrett	Officer	Oct 06 '25	Proposed Sale	13.35	100,583	1,342,783		Oct 06 04:32 PM
Azoy Alexander	Chief Accounting Officer	Sep 29 '25	Sale	13.00	2,831	36,803	27,363	Sep 30 06:59 PM
ALEXANDER AZOY	Officer	Sep 29 '25	Proposed Sale	12.84	2,831	36,350		Sep 29 04:36 PM
Azoy Alexander	Chief Accounting Officer	Sep 05 '25	Sale	11.88	1,579	18,758	30,194	Sep 05 07:48 PM
ALEXANDER AZOY	Officer	Sep 05 '25	Proposed Sale	11.56	1,579	18,253		Sep 05 04:24 PM
KANEKO YASUNORI	Director	Feb 27 '25	Buy	10.06	20,000	201,200	28,400	Feb 27 07:06 PM
ROSEN TERRY J	Chief Executive Officer	Feb 27 '25	Buy	10.18	19,800	201,465	2,554,160	Feb 27 07:05 PM
GILEAD SCIENCES, INC.	10% Owner	Feb 18 '25	Buy	11.00	1,363,636	14,999,996	31,424,760	Feb 20 07:42 PM

Open in Screener

XLO

Xilio Therapeutics Inc

Feb 12 • 04:00PM ET

0.5962

+0.0612 11.44 %

Healthcare • Biotechnology • USA • NASD

XLO Xilio Therapeutics Inc daily Stock Chart

Peers: BNTX VRTX MRNA AZN-D ALXO NBIX ARVN IMVT ADPT FOLD

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-0.66	Insider Own	56.42%	Shs Outstand	51.83M	Perf Week	14.68%
Market Cap	40.27M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	29.44M	Perf Month	-9.09%
Enterprise Value	-56.23M	PEG	-	EPS next Q	-	Inst Own	17.55%	Short Float	7.27%	Perf Quarter	-24.95%
Income	-58.49M	P/S	1.27	EPS this Y	-	Inst Trans	-4.85%	Short Ratio	4.26	Perf Half Y	-16.58%
Sales	31.80M	P/B	-	EPS next Y	-	ROA	-56.14%	Short Interest	2.14M	Perf YTD	-6.87%
Book/sh	-0.16	P/C	0.39	EPS next 5Y	-	ROE	-908.28%	52W High	1.70 -64.93%	Perf Year	-59.72%
Cash/sh	1.54	P/FCF	-	EPS past 3/5Y	26.76% -11.55%	ROIC	-	52W Low	0.50 18.53%	Perf 3Y	-80.13%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	94.77%	Volatility	9.20% 6.57%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-1.77	EPS Y/Y TTM	61.76%	Oper. Margin	-137.64%	ATR (14)	0.04	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.20	Sales Y/Y TTM	588.40%	Profit Margin	-183.90%	RSI (14)	48.88	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.20	EPS Q/Q	48.85%	SMA20	1.17%	Beta	-0.05	Target Price	2.00
Payout	-	Debt/Eq	-	Sales Q/Q	742.51%	SMA50	-7.49%	Rel Volume	3.71	Prev Close	0.54
Employees	64	LT Debt/Eq	-	Earnings	Nov 13 BMO	SMA200	-17.48%	Avg Volume	501.77K	Price	0.60
IPO	Oct 22, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-244.83% 2.50%	Trades		Volume	1,783,040	Change	11.44%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-06-25	Initiated	Leerink Partners	Outperform	$2
Dec-21-22	Initiated	Chardan Capital Markets	Buy	$7
Jan-10-22	Initiated	H.C. Wainwright	Buy	$36
Nov-16-21	Initiated	Raymond James	Outperform	$31
Nov-16-21	Initiated	Morgan Stanley	Overweight	$32
Nov-16-21	Initiated	Guggenheim	Buy	$40
Nov-16-21	Initiated	Cowen	Outperform

Feb-11-26 09:34PM	Xilio Therapeutics Announces Pricing of Underwritten Offering (GlobeNewswire) +11.44%
Jan-08-26 08:30AM	Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates (GlobeNewswire)
Nov-13-25 08:45AM	Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -9.28%
07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-12-25 08:25AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
09:05AM	Loading…
Nov-07-25 09:05AM	Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting (GlobeNewswire)
09:01AM	Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting (GlobeNewswire)
Nov-03-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.68% -5.66%
Oct-30-25 09:01AM	Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting (GlobeNewswire)
Oct-03-25 09:00AM	Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting (GlobeNewswire)
Oct-02-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-09-25 07:30AM	Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead (GlobeNewswire) +7.81%
Aug-14-25 08:35AM	Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 09:36AM	Snap downgraded, Leidos upgraded: Wall Street's top analyst calls (The Fly)
08:03AM	Loading…
Aug-04-25 08:03AM	Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors (GlobeNewswire)
Aug-01-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-28-25 05:05PM	Bristol Myers Squibb and Bain Capital Form New Immunology Company (The Wall Street Journal)
Jul-02-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-10-25 04:30PM	Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors (GlobeNewswire)
Jun-05-25 06:38PM	Xilio Therapeutics Announces Closing of $50.0 Million Public Offering (GlobeNewswire)
Jun-03-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-25 08:46AM	Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering (GlobeNewswire) -34.57%
06:11AM	Xilio Therapeutics Announces Proposed Public Offering (GlobeNewswire)
May-31-25 08:00AM	Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer (GlobeNewswire)
May-08-25 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results (GlobeNewswire) +8.03%
May-02-25 04:30PM	Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-23-25 04:30PM	Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting (GlobeNewswire) +5.55%
Apr-04-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-11-25 08:45AM	Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -6.20%
07:30AM	Loading…
07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-24-25 04:30PM	Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -5.13%
Feb-13-25 04:17AM	AbbVie and Xilio to collaborate on antibody-based immunotherapies (Pharmaceutical Technology) -12.84%
Feb-12-25 10:44AM	Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? (Benzinga) +125.27%
07:35AM	Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs (GlobeNewswire)
07:33AM	AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies (GlobeNewswire)
Feb-03-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.30%
Jan-22-25 09:00AM	Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire) -29.91%
Jan-21-25 05:05PM	Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer (GlobeNewswire) +11.40%
Jan-17-25 04:30PM	Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-10-25 05:00PM	Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-19-24 07:30AM	Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI (GlobeNewswire) +8.25%
Dec-16-24 07:30AM	Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer (GlobeNewswire)
Dec-09-24 09:55AM	After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright (Zacks)
Dec-03-24 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-24 09:15AM	Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors (GlobeNewswire) -19.38%
09:05AM	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-30-24 09:01AM	Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (GlobeNewswire) +38.38%
Oct-04-24 09:05AM	Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (GlobeNewswire) +7.51%
Oct-02-24 04:15PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-28-24 04:01PM	Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire) -10.98%
Aug-08-24 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-13-24 04:05PM	Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors (GlobeNewswire)
May-29-24 06:05AM	Gilead and Cartography enter deal to develop cancer therapies (Pharmaceutical Technology)
May-14-24 01:54PM	XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results (GlobeNewswire)
Apr-16-24 09:14AM	Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why (Zacks)
Apr-01-24 10:53PM	XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +41.67%
04:05PM	Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-28-24 11:10AM	Why Is Xilio Therapeutics (XLO) Stock up 168% Today? (InvestorPlace) +69.01%
07:05AM	Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing (GlobeNewswire)
07:00AM	Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program (GlobeNewswire)
06:45AM	Gilead bets on Xilio cancer drug as biotech restructures (BioPharma Dive)
Feb-28-24 04:01PM	Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +5.60% +7.42%
Jan-31-24 04:01PM	Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-08-24 07:30AM	Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies (GlobeNewswire)
Dec-07-23 07:30AM	Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data (GlobeNewswire)
Nov-09-23 04:01PM	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results (GlobeNewswire) -13.04% -10.63%
Nov-03-23 12:00PM	Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors (GlobeNewswire)
Oct-31-23 09:15AM	Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting (GlobeNewswire)
Sep-27-23 05:02PM	Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting (GlobeNewswire)
Sep-05-23 08:30AM	Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer (GlobeNewswire)
07:30AM	Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-18-23 04:27AM	Q2 2023 Xilio Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 04:05PM	Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer (GlobeNewswire)
May-25-23 05:01PM	Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors (GlobeNewswire)
May-09-23 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results (GlobeNewswire)
Apr-03-23 04:05PM	Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.09%
Mar-02-23 04:05PM	Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -7.37%
Feb-27-23 07:30AM	Xilio Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.72%
Feb-16-23 07:30AM	Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit (GlobeNewswire)
Feb-02-23 07:30AM	Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day (GlobeNewswire)
Jan-26-23 05:30AM	Institutions profited after Xilio Therapeutics, Inc.'s (NASDAQ:XLO) market cap rose US$33m last week butprivate equity firms profited the most (Simply Wall St.)
Jan-25-23 09:45AM	These 2 Strong Buy Penny Stocks Are on Track for Massive Gains, Say Analysts (TipRanks) +36.92%
Nov-23-22 07:30AM	Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12 (GlobeNewswire) +7.94%
Nov-09-22 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-04-22 07:30AM	Xilio Therapeutics to Present at Cowen 6th Annual IO Next Summit (GlobeNewswire)
Sep-22-22 04:05PM	Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference (GlobeNewswire)
Sep-15-22 04:05PM	Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors (GlobeNewswire) +15.38%
Sep-06-22 04:05PM	Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire) +8.21%
Aug-11-22 09:41AM	Is Xilio Therapeutics (NASDAQ:XLO) In A Good Position To Invest In Growth? (Simply Wall St.)
Aug-09-22 07:30AM	Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results (GlobeNewswire) -26.22%
Jun-16-22 07:30AM	Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President (GlobeNewswire)
May-18-22 07:30AM	Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) -9.56%
May-17-22 07:30AM	Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer (GlobeNewswire) -5.18%
May-12-22 07:30AM	Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results (GlobeNewswire)
Apr-07-22 06:30AM	Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-01-22 06:30AM	Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) -7.56%
Feb-28-22 06:30AM	Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference (GlobeNewswire) -10.42%

Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shannon James Samuel	Director	Jun 16 '25	Buy	0.69	45,000	30,870	45,000	Jun 18 04:57 PM
Shannon James Samuel	Director	Jun 17 '25	Buy	0.69	25,000	17,215	70,000	Jun 18 04:57 PM
Russo Rene	PRESIDENT AND CEO	Jun 16 '25	Buy	0.68	36,289	24,680	281,172	Jun 18 04:56 PM

Open in Screener

KYTX

Kyverna Therapeutics Inc

Feb 12 • 04:00PM ET

7.36

-0.19 -2.52 %

Healthcare • Biotechnology • USA • NASD

KYTX Kyverna Therapeutics Inc daily Stock Chart

Peers: MRNA AMGN VRTX JNJ REGN GILD BMRN PFE BMY NVAX

| Held by: VTI VXF IBB SURI SCHA IWC AVSC DFAS SCHB DFAC

Index	-	P/E	-	EPS (ttm)	-3.72	Insider Own	38.64%	Shs Outstand	43.79M	Perf Week	1.24%
Market Cap	420.47M	Forward P/E	-	EPS next Y	-3.47	Insider Trans	1.11%	Shs Float	35.05M	Perf Month	-15.01%
Enterprise Value	254.35M	PEG	-	EPS next Q	-0.85	Inst Own	29.82%	Short Float	10.00%	Perf Quarter	5.14%
Income	-160.99M	P/S	-	EPS this Y	-10.93%	Inst Trans	3.73%	Short Ratio	2.35	Perf Half Y	112.10%
Sales	0.00M	P/B	2.12	EPS next Y	6.11%	ROA	-61.17%	Short Interest	3.51M	Perf YTD	-21.70%
Book/sh	3.47	P/C	2.46	EPS next 5Y	1.16%	ROE	-70.82%	52W High	13.67 -46.16%	Perf Year	176.69%
Cash/sh	3.00	P/FCF	-	EPS past 3/5Y	-75.88% -	ROIC	-105.03%	52W Low	1.78 313.48%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.88% 8.95%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-21.22%	Oper. Margin	-	ATR (14)	0.71	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.16	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	41.81	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.16	EPS Q/Q	-6.05%	SMA20	-12.86%	Beta	3.42	Target Price	29.60
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-12.79%	Rel Volume	0.25	Prev Close	7.55
Employees	112	LT Debt/Eq	0.01	Earnings	Nov 12 AMC	SMA200	34.87%	Avg Volume	1.49M	Price	7.36
IPO	Feb 08, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.47% -	Trades		Volume	381,589	Change	-2.52%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-25	Initiated	William Blair	Outperform
May-27-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
Oct-10-24	Initiated	UBS	Buy	$13
Oct-09-24	Initiated	Rodman & Renshaw	Buy	$16
Jul-03-24	Initiated	H.C. Wainwright	Neutral	$8
Mar-04-24	Initiated	Wells Fargo	Overweight	$44
Mar-04-24	Initiated	Morgan Stanley	Overweight	$40
Mar-04-24	Initiated	Leerink Partners	Outperform	$48
Mar-04-24	Initiated	JP Morgan	Overweight	$39

Feb-03-26 08:00AM	Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer (GlobeNewswire)
Jan-12-26 08:00AM	Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 08:00AM	Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference (GlobeNewswire) -7.30%
Dec-30-25 07:58AM	Kyverna Therapeutics Stock Up 41% in a Month: Here's Why (Zacks)
Dec-17-25 09:24AM	Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock (GlobeNewswire) -32.52%
10:10AM	Loading…
Dec-16-25 10:10AM	KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data (Zacks) -5.36%
09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks)
Dec-15-25 04:01PM	Kyverna Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +23.23%
06:30AM	Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome (GlobeNewswire)
03:41AM	Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease (BioPharma Dive)
Dec-14-25 02:30PM	Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome (GlobeNewswire)
Dec-12-25 07:30AM	2 Strong Buy Biotech Stocks With 208% to 329% Upside Potential (Barchart) +5.02%
Nov-12-25 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire) -11.60%
Nov-10-25 08:00AM	Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-03-25 08:00AM	Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance (GlobeNewswire)
06:30AM	Loading…
Oct-29-25 06:30AM	Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 (GlobeNewswire) -5.78%
Oct-25-25 11:00AM	Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 (GlobeNewswire)
Oct-22-25 08:00AM	Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis (GlobeNewswire) -6.58%
Oct-17-25 09:59AM	Wells Fargo Raises Kyverna Therapeutics (KYTX) PT to $27 on Confidence in KYV-101 Stiff Person Syndrome Trial Readout (Insider Monkey) -5.42%
Sep-24-25 09:05AM	Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS (GlobeNewswire)
Sep-15-25 01:02PM	Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 (GlobeNewswire)
Aug-28-25 08:00AM	Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event (GlobeNewswire)
Aug-25-25 04:02PM	Kyverna Therapeutics to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-12-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire) +14.90%
Aug-01-25 09:00AM	BioMarin Announces Appointment of Ian T. Clark to Board of Directors (PR Newswire)
Jul-29-25 10:23AM	Kyverna Appoints New CFO to Guide Next Growth Phase (Insider Monkey) -11.09%
08:30AM	Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise (PR Newswire)
Jun-30-25 09:00AM	Kyverna Therapeutics Announces Appointment of New Chief Financial Officer (PR Newswire) -6.40%
May-28-25 04:02PM	Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference (PR Newswire)
May-16-25 06:36AM	Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff (BioPharma Dive) +6.42%
04:02PM	Loading…
May-13-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results (PR Newswire) -7.33%
Apr-17-25 07:38AM	Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-27-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire) -5.80% -15.07%
Mar-24-25 09:13AM	Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-21-25 11:29AM	Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 (SeekingAlpha)
08:32AM	Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-18-25 04:48PM	Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-17-25 03:01PM	Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-03-25 04:05PM	Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference (PR Newswire) -8.80%
Feb-10-25 12:00PM	What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock (Zacks)
Jan-21-25 04:05PM	Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer (PR Newswire)
Jan-17-25 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Jan-13-25 07:30AM	Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-08-25 08:00AM	Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors (GlobeNewswire)
Jan-07-25 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Jan-06-25 04:05PM	Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference (PR Newswire) -7.07%
Dec-27-24 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Dec-19-24 12:16PM	Investors in Kyverna Therapeutics, Inc. Should Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights KYTX (GlobeNewswire)
Dec-13-24 04:05PM	Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth (PR Newswire)
Dec-09-24 06:38PM	Kyverna Therapeutics, Inc. Investors Who Have Lost Money Should Contact Block and Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit (GlobeNewswire) +6.81% -5.56%
Nov-14-24 10:01AM	Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024 (PR Newswire) -5.14%
Nov-13-24 04:14PM	Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (PR Newswire)
Oct-21-24 08:00AM	Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors (PR Newswire) -7.80%
Oct-19-24 11:13AM	Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy (Insider Monkey)
Oct-10-24 03:05PM	JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc (GuruFocus.com)
Sep-18-24 08:00AM	Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024 (PR Newswire)
Sep-16-24 08:00AM	Kyverna Therapeutics Announces Leadership Update (PR Newswire)
06:58AM	Kyverna swaps CEOs, leaning on Kite veterans to lead next chapter (BioPharma Dive)
Aug-21-24 04:05PM	Kyverna Therapeutics to Participate in Upcoming September Investor Conferences (PR Newswire) +13.36% -5.36%
Aug-12-24 04:08PM	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (PR Newswire) +7.20%
04:05PM	Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis (PR Newswire)
Jul-16-24 11:33AM	Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate (Pharmaceutical Technology) +11.71%
08:52AM	Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product (Zacks)
Jul-15-24 04:05PM	Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome (PR Newswire)
Jun-20-24 08:55AM	Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial (PR Newswire) +7.93%
Jun-17-24 04:05PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS) (PR Newswire) -17.21% -5.70%
Jun-10-24 04:05PM	Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology (PR Newswire)
Jun-07-24 08:55AM	Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 (PR Newswire)
May-14-24 10:54PM	KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +5.95%
04:05PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-11-24 05:01PM	Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases (PR Newswire)
Mar-29-24 02:59PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med (PR Newswire)
Mar-26-24 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results (PR Newswire) +6.97%
Mar-14-24 07:00AM	Why That Hot Biotech IPO Could Be a Winner (The Wall Street Journal)
Mar-07-24 07:26PM	Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis (PR Newswire)
06:14PM	How Kyverna is positioned for success on autoimmune therapy: CEO (Yahoo Finance Video)
Feb-12-24 04:39PM	Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-07-24 10:29PM	Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering (PR Newswire)

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SEIDENBERG BETH C	Director	Dec 18 '25	Buy	7.50	133,333	999,998	869,317	Dec 22 11:43 AM
Westlake BioPartners Opportuni	10% Owner	Dec 18 '25	Buy	7.50	133,333	999,998	869,317	Dec 22 11:42 AM
Walker Karen Marie	Chief Technology Officer	Dec 15 '25	Option Exercise	4.83	23,998	115,910	46,634	Dec 17 08:30 PM
Walker Karen Marie	Chief Technology Officer	Dec 15 '25	Sale	12.20	23,998	292,776	22,636	Dec 17 08:30 PM
KAREN WALKER	Officer	Dec 15 '25	Proposed Sale	8.78	23,998	210,702		Dec 15 04:16 PM

ASMB

Assembly Biosciences Inc

RCUS

Arcus Biosciences Inc

XLO

Xilio Therapeutics Inc

KYTX

Kyverna Therapeutics Inc

Upgrade your FINVIZ experience